Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer: Impact on Residual GGO Lesions

被引：0
|
作者：
Ma, H. [1 ]
Huang, H. [2 ]
Feng, Y. [2 ]
Chen, S. [2 ]
Li, G. [2 ]
机构：
[1] Soochow Univ, Dushu Lake Hosp, Suzhou, Peoples R China
[2] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Adjuvant; Aumolertinib; Ground-glass opacity;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP07.05-05
引用
收藏
页码：S559 / S560
页数：2
相关论文
共 50 条
  • [1] Aumolertinib as adjuvant therapy in postoperative EGFR-mutated non-small cell lung cancer
    Zhang, Q.
    He, C.
    He, T.
    Wang, Y.
    Lv, W.
    Hu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S73 - S73
  • [2] Adjuvant aumolertinib in resected EGFR-mutated non-small cell lung cancer: A multiple-center real-world experience
    Zhang, Q.
    Ke, L.
    Huang, S.
    Yang, Y.
    He, T.
    Sun, H.
    Wu, Z.
    Zhang, X.
    Zhang, H.
    Lv, W.
    Hu, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S98 - S98
  • [3] Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
    Patel, Shruti R.
    Neal, Joel W.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (07) : 1631 - 1635
  • [4] Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
    Shepherd, Annemarie F.
    Preeshagul, Isabel R.
    Shaverdian, Narek
    Wu, Abraham J.
    Gelblum, Daphna Y.
    Gomez, Daniel R.
    Rimner, Andreas
    Simone, Charles B., II
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (23)
  • [5] Adjuvant Osimertinib in Resected EGFR-Mutated Stage IBeIIIA Non-Small Cell Lung Cancer: Updated ADAURA Results
    Herbst, R. S.
    Wu, Y. -L.
    Grohe, C.
    John, T.
    Majem, M.
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S. -W.
    Yu, C. -J.
    Vu, H. V.
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A.
    Huang, X.
    Tsuboi, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E4 - E4
  • [6] Aumolertinib as Neoadjuvant Therapy for EGFR-mutated Non-Small Cell Lung Cancer: A Subcohort Analysis of the PURPOSE Trial
    Wang, Y. -Y.
    Gu, Z. -T.
    Bao, F. -C.
    Mao, T.
    Ji, C. -Y.
    Fang, W. -T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S565 - S565
  • [7] Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Tsuboi, Masahiro
    He, Jie
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Laktionov, Konstantin
    Kim, Sang-We
    Kato, Terufumi
    Vu, Huu-Vinh
    Lu, Shun
    Lee, Kye-Young
    Akewanlop, Charuwan
    Yu, Chong-Jen
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Zeng, Lingmin
    Hodge, Rachel
    Atasoy, Ajlan
    Rukazenkov, Yuri
    Herbst, Roy S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1711 - 1723
  • [8] Adjuvant Osimertinib in EGFR-Mutated Non-Small-Cell Lung Cancer
    Planchard, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1780 - 1782
  • [9] Treatment strategy of EGFR-mutated non-small cell lung cancer
    Tanaka, Fumihiro
    Yoneda, Kazue
    Takenaka, Masaru
    Kuroda, Koji
    JOURNAL OF THORACIC DISEASE, 2022, 14 (03) : 602 - 606
  • [10] Emerging drugs for EGFR-mutated non-small cell lung cancer
    Sukrithan, Vineeth
    Deng, Lei
    Barbar, Alexander
    Cheng, Haiying
    EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (01) : 5 - 16
12345